NRx Pharmaceuticals granted request for transfer of listing to Nasdaq Capital

NRx Pharmaceuticals announced that the company was notified by Nasdaq that the Nasdaq Hearings Panel granted the company’s request for the transfer of its listing to Nasdaq Capital Market, subject to the company evidencing compliance with all applicable criteria for continued listing on the Capital Market tier, including the $35M in market value of listed securities, or MVLS, and the $1.00 bid price requirements. The company believes it has already satisfied the market value of listed securities requirement and is working to evidence compliance with the minimum bid price requirement by April 16, as required by the Panel’s decision. An issuer must evidence compliance with the minimum threshold for at least ten consecutive business days to be deemed by Nasdaq to have complied with the applicable requirement.